Skip to main content

Table 1 Socio-demographics and disease characteristics of participants and non-participants

From: Health related quality of life and parental perceptions of child vulnerability among parents of a child with juvenile idiopathic arthritis: results from a web-based survey

  Participants Non-participants  
PARENTS N M SD N M SD  
Age (years) 155 41.99 5.40     
  N %   N %   p
Country of birth parents (Netherlands) 139 83.7   65 61.9   <.001b
Gender (female) 147 87.5      
Married/living together 158 94.0      
Education        
 Low 22 13.1      
 Middle 86 51.2      
 High 60 35.7      
Number of children        
 1 22 13.1      
 2-3 135 80.3      
 > 3 11 6.6      
CHILDREN N M SD N M SD p
Age (years) 168 11.48 4.56 105 13.28 3.87 <.001a
Age of disease onset 165 7.40 4.42 104 8.61 4.46 .03a
Age of diagnosis 168 8.58 4.69 103 9.72 4.52 .05a
  N %   N %   p
Gender (female) 113 67.3   65 61.9   .34b
JIA subtype N %   N %   p
 Oligo-articular JIA, persistent 40 13.8   19 18.1   .26b
 Oligo-articular JIA, extended 21 12.5   12 11.4   .79b
 Poly-articular JIA, RF negative 66 39.4   46 43.8   .46b
 Poly-articular JIA, RF positive 5 3.0   4 3.8   .71b
 Systemic JIA 7 4.2   3 2.9   *
 Enthesitis related Arthritis 18 10.7   11 10.5   .95b
 Undifferentiated JIA 9 5.3   8 7.7   .50b
 Chronic arthritis with other autoimmune inflammatory disease 2 1.2   2 1.9   *
  N Median (range) N Median (range) p   
Time between symptom onset and diagnosis of JIA (months) 165 0.55 (0–8.78) 102 0.47 (0.1-10.26)    .19c
Disease duration (years) 165 3.46 (0.28-14.82) 102 3.77 (0.45-14.13)    .15c
Physician disease activity (VAS score range 0–100) 165 15.00 (0–84) 102 17.00 (0–94)    .85c
Number of joints with arthritis N %   N %   p
No arthritis 76 45.2   46 43.8   .82b
 Monoarthritis (1 joint) 21 12.5   18 17.1   .29b
 Oligoarthritis (2–4 joints) 45 26.8   22 21.0   .28b
 Polyarthritis (>4 joints) 23 13.7   19 18.1   .57b
 Uveitis presenting during disease course 8 4.8   9 8.6   .45b
Medication at time point of evaluation N %   N %   p
 No medication 13 7.7   16 15.2   .05b
 NSAID 98 58.3   47 44.8   .029b
 DMARDS (including methotrexate, sulfasalazine) 131 78.0   76 72.4   .38b
 Anti-TNF 24 14.3   1 9.5   *
 DMARDS and Biological (Anti-TNF) 21 12.5   9 8.6   .31b
  1. a = independent samples T-test, b = Chi2, c = Mann-Whitney U test, * = less than 5 cases in a cell.
  2. Abbrevations: JIA = Juvenile Idiopathic Arthritis, VAS = Visual Analogue Scale, NSAID = Non Steroid Anti-Inflammatory Drug, DMARD = Disease Modifying Anti-Rheumatic Drug: methotrexate, sulfasalazine, Anti-TNF = anti-Tumor Necrosis Factor: etanercept, adalimumab, infliximab.